Mild to moderate essential hypertension
Conditions
Interventions
Experimental group:On the basis of the fixed drug treatment regimen, the subjects were treated with a semiconductor laser therapy instrument (model specification: DWS-E-810-ND) developed by Zhejiang D
Control group:Subjects were treated with a fixed drug regimen.
Sponsors
Zhejiang Hospital Affiliated to Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-75 years old (inclusive), gender is not limited; 2) The sitting blood pressure in the office meets the diagnostic criteria for mild and moderate essential hypertension: 90mmHg= sitting diastolic blood pressure (2~3 times average) =109mmHg and/or 140mmHg= sitting systolic blood pressure (2~3 times average) =179mmHg (see the 2018 revised diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Hypertension); 3) Those who have been diagnosed with mild to moderate essential hypertension and the current or planned medication regimen is monotherapy (A (ACE inhibitor or ARB) or B (ß-receptor blocker) or C (CCB)) or combination therapy (A + B or A + C); 4) BMI index 18-30kg/m2; 5) Subjects agree to participate in this trial and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients diagnosed with secondary hypertension and apnea syndrome; 2) Patients suspected of malignant hypertension, hypertensive emergency, and hypertensive emergency; 3) those who were treated with lifestyle intervention only as recommended by the investigator (such as reducing sodium intake, not drinking too much alcohol, eating more fruits/vegetables, exercising properly, controlling weight, quitting smoking, reducing mental stress, maintaining psychological balance, etc.); 4) Patients with hemorrhagic tendency or coagulation dysfunction (prothrombin time PT=18s), thrombocytopenia (PLT40 cigarettes/day); 8) Patients with severe anemia (Hb=60g/L); 9) Those with a history of arrhythmia, atrial fibrillation, atrial flutter, etc. within 6 months; 10) Those with ALT and AST greater than 1.5 times of the upper limit of normal during the screening period; 11) Those with acute infection; 12) Cancer patients; 13) Patients with severe cerebrovascular diseases; 14) Those with mental illness or medical history; 15) Patients with nasal bleeding, mucosal injury, edema, nasal septum curvature, and nasal tumor; 16) Cardiac insufficiency (NYHA classification = grade III), wearing a pacemaker; 17) Those who are allergic to light or allergic in the past; 18) Pregnant or lactating women and those who plan to become pregnant within 6 months; 19) Those who have participated in other interventional clinical trials within 3 months before the start of this trial; 20) Those who are considered by the investigator to be inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure control is effective;Systolic and diastolic blood pressure levels;Device performance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of improvement in clinical symptoms; | — |
Countries
China
Contacts
Public ContactYan Jing
Zhejiang Hospital Affiliated to Zhejiang University School of Medicine
Outcome results
None listed